Home > Insider Trading > Filing (0000950170-24-078468)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1719714	Mereo Biopharma Group Plc	MREO	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1553352	A. John Lewicki	C/O Mereo Biopharma Group Plc 4Th Floor, One Cavendish Place London X0 W1G 0QF	Chief Scientific Officer	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
American Depositary Shares Representing Ordinary Shares	Disposition	2024-06-25	7,416	$3.69	65,587	No	4	S	Direct
American Depositary Shares Representing Ordinary Shares	Disposition	2024-06-26	16,808	$3.39	48,779	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
American Depositary Shares Representing Ordinary Shares	14,196	Indirect	By The Lewicki Family Living Trust dated December 6, 2000

Footnotes

Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The ReportingPerson undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, fullinformation regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive.